EYPT vs. TXG, TRNS, CTKB, LAB, AEHR, SENS, ALNT, QTRX, QSI, and NAUT
Should you be buying EyePoint Pharmaceuticals stock or one of its competitors? The main competitors of EyePoint Pharmaceuticals include 10x Genomics (TXG), Transcat (TRNS), Cytek Biosciences (CTKB), Standard BioTools (LAB), Aehr Test Systems (AEHR), Senseonics (SENS), Allient (ALNT), Quanterix (QTRX), Quantum-Si (QSI), and Nautilus Biotechnology (NAUT). These companies are all part of the "measuring and control equipment" industry.
EyePoint Pharmaceuticals vs.
10x Genomics (NASDAQ:TXG) and EyePoint Pharmaceuticals (NASDAQ:EYPT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, community ranking, dividends, analyst recommendations, institutional ownership and media sentiment.
EyePoint Pharmaceuticals received 410 more outperform votes than 10x Genomics when rated by MarketBeat users. Likewise, 70.24% of users gave EyePoint Pharmaceuticals an outperform vote while only 53.40% of users gave 10x Genomics an outperform vote.
84.7% of 10x Genomics shares are held by institutional investors. Comparatively, 99.4% of EyePoint Pharmaceuticals shares are held by institutional investors. 10.0% of 10x Genomics shares are held by company insiders. Comparatively, 4.7% of EyePoint Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
10x Genomics presently has a consensus target price of $23.86, suggesting a potential upside of 58.20%. EyePoint Pharmaceuticals has a consensus target price of $26.63, suggesting a potential upside of 255.95%. Given EyePoint Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe EyePoint Pharmaceuticals is more favorable than 10x Genomics.
10x Genomics has a net margin of -28.93% compared to EyePoint Pharmaceuticals' net margin of -226.57%. 10x Genomics' return on equity of -25.07% beat EyePoint Pharmaceuticals' return on equity.
In the previous week, 10x Genomics had 11 more articles in the media than EyePoint Pharmaceuticals. MarketBeat recorded 16 mentions for 10x Genomics and 5 mentions for EyePoint Pharmaceuticals. 10x Genomics' average media sentiment score of 0.67 beat EyePoint Pharmaceuticals' score of 0.46 indicating that 10x Genomics is being referred to more favorably in the media.
10x Genomics has a beta of 1.83, indicating that its stock price is 83% more volatile than the S&P 500. Comparatively, EyePoint Pharmaceuticals has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500.
EyePoint Pharmaceuticals has lower revenue, but higher earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than EyePoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
10x Genomics beats EyePoint Pharmaceuticals on 10 of the 19 factors compared between the two stocks.
Get EyePoint Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
EyePoint Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:EYPT) was last updated on 1/18/2025 by MarketBeat.com Staff
Free EYPT Stock Alerts